Has Anna Podolanczuk, MD received payments from drug or device companies?

Yes. Drug and device makers reported $116,483 in general payments to Anna Podolanczuk, MD across 86 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anna Podolanczuk, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anna Podolanczuk, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anna Podolanczuk, MD

Critical Care Medicine · New York, NYNPI 1841441714

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 50.7% of the total. Reporting peaked in 2023 at $51,886 and has fallen 53.2% since, to $24,260 in 2025. Among critical care medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$116,483in general payments, 2019–2025

Across 86 payments — averaging $1354.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim International GmbH$59K
Boehringer Ingelheim$40K
United Therapeutics Corporation$9K
Regeneron$7K
F. Hoffmann-la Roche AG$2K
AstraZeneca$25

$266,873in research payments, 2019–2025

Across 52 payments — averaging $5132.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

GSK$139K
United Therapeutics Corporation$105K
Regeneron$23K

What the payments were for

Consulting fees$58,90551%
Speaking & faculty fees$26,74023%
Travel & lodging$28,52024%
Food & beverage$2,3062%
Education$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim International GmbH	31	$59,084
Boehringer Ingelheim	21	$39,758
United Therapeutics Corporation	22	$9,156
Regeneron	9	$6,500
F. Hoffmann-la Roche AG	1	$1,960
AstraZeneca	2	$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OFEV$78,798
Esbriet$1,960
TYVASO$1,256
ORENITRAM$1,153
REMODULIN$1,153

How this compares

$116,483 in reported general payments places this provider in the 95th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York →

Medicare billing

Part B allowed, 2024

$43,818

Medicare patients

140

Services billed

275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OfevNintedanib Esylate	54	$678,475
Pirfenidone	27	$160,967
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	25	$15,365
Mycophenolate Mofetil	46	$7,716
Breo ElliptaFluticasone/Vilanterol	11	$4,410
Albuterol Sulfate HfaAlbuterol Sulfate	16	$495
Fluticasone Propionate	15	$222
Prednisone	25	$119
Pantoprazole Sodium	14	$89
Omeprazole	20	$76

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Boehringer IngelheimOfev	$39,758	$678,47554 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 442 critical care medicine providers in New York.

Other critical care medicine in New York

Roxana SulicaNew York$211K
Jan BakkerNew York$49K
Robert SladenNew York$40K
Neil HalpernNew York$29K
Singwu LawNew York$20K
Peter SalgoNew York$18K
Stephen PastoresNew York$17K
Arvin ChinNew York$17K
Nina PatelNew York$17K
Jeremy BeitlerNew York$15K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →